On-DNA Kinetics at Philochem: What Biacore Cannot Deliver
Concrete kinetic wins at Philochem
Nicholas Favalli, Group Leader in the Chemistry R&D team at Philochem AG, a Zurich-based pharmaceutical company specialised in small-molecule cancer therapeutics, describes how his team uses focal molography for DEL hit validation.
The DEL screening bottleneck
Philochem synthesises libraries of millions to billions of compounds and screens them via affinity selection against targets of interest. A single selection can return thousands of hits, far too many to resynthesise off-DNA, and off-DNA resynthesis itself is cumbersome.
Where DNA-tag chemistry breaks conventional methods
On-DNA validation with conventional biophysics runs into two hard problems:
- Fluorescence polarisation: dissociation constants (KD) come out a factor of 10 or more higher than the same molecule without DNA, due to steric hindrance from the tag.
- Biacore SPR: DNA is negatively charged, so chip immobilisation of the compound is unstable. When the protein is immobilised on the chip instead, koff appears much faster because the DNA does not interact well with the chip surface.
Why focal molography solves this
Focal molography exploits the DNA tag for annealing to the chip, the same tag that broke Biacore is now the coupling mechanism. Kinetic parameters kon and koff can be measured directly on-DNA, delivering kinetic profiles that Biacore could not resolve and identifying molecules that fluorescence polarisation missed.
Usability in daily practice
Favalli emphasises that the MACS Matchmaker instrument is very user-friendly. Sample preparation is loading vials with target protein or DNA pool into a rack, and the process is fully automated from there. Focal molography will be an orthogonal methodology at Philochem, complementing the fluorescence polarisation and ELISA methods already established in-house.
More videos and webinars
DEL Hit Validation: The On-DNA Advantage
Joshua Alper, PhD
Alper Consulting, LLC ·Jul 2026
Focal Molography in Complex Media
Prof. Dominik Meinel
FHNW Muttenz ·May 2026
Novalix 2025: Biophysics in Drug Discovery
Dr. Andreas Frutiger
lino Biotech AG ·Jun 2025